All In Biotech

NDA 017422 · Avet Lifesciences

Bicnu

Carmustine · Injection

Novel

Last checked: Nov 20, 2026Latest source record: Apr 30, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1977

Mar 7, 1977

Approved uses

1

Original approval plus efficacy supplements

Registered trials

259

44 Phase 3, 18 recruiting

FAERS reports

4,156

4,089 serious, 1,117 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: MYELOSUPPRESSION and PULMONARY TOXICITY Myelosuppression Carmustine for Injection, USP causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections, [see Warnings and Precautions (5.1) and Adverse Reactions (6) ] . Monitor blood counts weekly for at least 6 weeks after each dose. Adjust dosage based on nadir blood counts from the prior dose [see Dosage and Administration (2.1) ] . Do not administer a repeat course of Carmustine for Injection until blood counts recover. Pulmonary Toxicity Carmustine for Injection causes dose-related pulmonary toxicity. Patients receiving greater than 1400 mg /m 2 cumulative dose are at significantly higher risk than those receiving less. Delayed pulmonary toxicity can occur years after treatment, and can result in death, particularly in patients treated in...

What it is approved for

From the label in effect Apr 9, 2026.

Carmustine for Injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors ( 1 ) Multiple myeloma-in combination with prednisone ( 1 ) Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs ( 1 ) Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs ( 1 ) Carmustine for Injection, USP is indicated as palliative therapy as a single agent or in established combination therapy in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. Multiple myeloma in combination with prednisone. Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.

Mechanism: The mechanism of action of carmustine is not fully understood. While carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. The metabolites may contribute to antitumor activity and toxicities of carmustine.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 7, 1977 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • BICNU · CARMUSTINE 100MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Carmustine" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use510
  • febrile neutropenia400
  • myelodysplastic syndrome298
  • disease progression269
  • mucosal inflammation256
  • thrombocytopenia232
  • pyrexia209
  • neutropenia206
  • pneumonia199
  • drug ineffective197
  • acute myeloid leukaemia172
  • infection165

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200484
200554
200635
200773
200898
200992
201069
2011132
2012128
201384
201461
2015132
2016102
2017223
2018315
2019336
2020367
2021309
2022280
2023432
2024293
2025229
2026228

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Bicnu* (Carmustine*) · HCPCS J9050

2024 spending

$147K

Beneficiaries

72

104 claims

Per beneficiary

$2,048

2024 ASP limit $315.36 per unit

View as table
YearSpending
2020$799,176
2021$917,156
2022$449,580
2023$175,669
2024$147,438

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 435 on PubMed

Sponsor: Avet Lifesciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.